Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Nasdaq

Analyst Ratings for Replimune Group

Analysts have provided the following ratings for Replimune Group (NASDAQ:REPL) within the last quarter:

Benzinga

Analyst Ratings for Intellia Therapeutics

Over the past 3 months, 8 analysts have published their opinion on Intellia Therapeutics (NASDAQ:NTLA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Expert Ratings for Principal Finl Gr

Analysts have provided the following ratings for Principal Finl Gr (NASDAQ:PFG) within the last quarter:

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Where Arrowhead Pharmaceuticals Stands With Analysts

Within the last quarter, Arrowhead Pharmaceuticals (NASDAQ:ARWR) has observed the following analyst ratings:

Benzinga

Here's How Much You Would Have Made Owning Activision Blizzard Stock In The Last 15 Years

Activision Blizzard (NASDAQ:ATVI) has outperformed the market over the past 15 years by 8.33% on an annualized basis producing an average annual return of 14.78%. Currently, Activision Blizzard has a market capitalization of $60.13 billion.

Benzinga

Expert Ratings for Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings within the last quarter:

Benzinga

Analyzing Enphase Energy's Short Interest

Enphase Energy's (NASDAQ:ENPH) short percent of float has risen 6.9% since its last report. The company recently reported that it has 4.08 million shares sold short, which is 3.1% of all regular shares that are available for trading.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Zoom Beats Estimates, But Could Have Rough Year: What 8 Analysts Have To Say

Quarterly revenue and earnings per share from Zoom Video Communications (NASDAQ: ZM) came in better than anticipated from analysts. Here are the key takeaways from analysts on what’s next for the video technology company.

Benzinga

ASX closes higher, HESTA supports Cannon-Brookes on AGL demerger

Australian shares climb on Wednesday after a mixed session on Wall Street that saw falling tech stocks and fears of a US recession.

ABC News

Norwegian Cruise Line And Caesars Entertainment Lead The S&P 500 Lower: Today's Winners And Losers

U.S. indices finished Tuesday's trading session lower amid a continued sell-off in stocks.

Benzinga

Cingulate Concludes Enrollment In Early Stage Anxiety Trial

Cingulate Inc. (NASDAQ: CING) has completed enrollment in its study to determine the appropriate formulation of its third asset, CTx-2103, for the management of anxiety-related disorders. The early stage study has enrolled 12 patients after the initiation early this month.

Benzinga

Wells Fargo Lists Its Picks In the Fintech Universe - See Which Stocks Made the Cut

Wells Fargo analyst Jeff Cantwell's top five fintech companies were WEX Inc (NYSE: WEX), FleetCor Technologies, Inc (NYSE: FLT), Fidelity National Information Service

Benzinga

Chinese Social Media Weibo Bans Another Business Leader After He Questions China's Zero Covid Policy

Weibo Corp (NASDAQ:WB) banned Trip.Com Group Limited (NASDAQ:TCOM) co-founder and Chair James Liang for alleged violation of laws, Reuters reports. The social media company neither elaborated on the violation nor cited the reasons behind the ban. Liang had recently questioned the wisdom of the country's zero-COVID strategy as the country's Presidential election draws closer. Also…

Benzinga

Here's Why Quantum Computing Shares Are Trading Higher Today

Quantum Computing Inc (NASDAQ:QUBT) agreed to acquire QPhoton, a quantum photonics innovation company. QPhoton developed a series of quantum photonic systems (QPS). QCI will issue to QPhoton's stockholders aggregate merger consideration consisting of 5.8 million shares, 2.4 million preferred shares convertible into 23.8 million shares, and warrants exercisable at a purchase price of…

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

AppTech Shares Gain As It Closes Acquisition Of Hothand

AppTech Payments Corp (NASDAQ:APCX) announced the closing of its acquisition of Hothand Inc. AppTech now owns Hothand's portfolio of twelve patents focused on delivering, purchasing, or requesting any products or services within specific geolocation and time parameters provided by a consumer's cell phone anywhere in the U.S. Hothand is a patent-holding company that…

Benzinga

Here's Why Mizuho Remains Incrementally Positive On Uber, Meta, Baidu, JD

Mizuho analyst James Lee recently met with investors and discussed U.S. and China internet coverage. With concerns about U.S. consumer demand and economic outlook, Lee senses that sentiment on China's Internet is improving.

Benzinga

Why Alphabet Stock Is Sliding Today

Alphabet Inc (NASDAQ: GOOG) (NASDAQ: GOOGL) shares are trading lower Tuesday after Snap Inc (NYSE: SNAP) said it expects to miss its previ

Benzinga

SVB Sees De-Risked Opportunity For This Newly Listed Norovirus Vaccine

SVB Leerink is initiating coverage of HilleVax Inc (NASDAQ:HLVX) shares with an Outperform rating and a $30 price target. The analyst believes the company’s potentially first-in-class infant norovirus vaccine HIL214 represents a uniquely de-risked opportunity. It estimates $625 million in risk-adjusted infant HIL214 sales in 2030E ($1 billion unadjusted). The outlook is supported by…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Why Roku Shares Are Falling Today

Roku Inc (NASDAQ: ROKU) shares are trading lower Tuesday after Snap Inc (NYSE: SNAP) said it expects to miss its previously-issued guidance.

Benzinga

SVB Sees Strategic Value In This Stock As M&A Target In Autoimmune Space

SVB Securities initiated coverage on Argenx SE (NASDAQ:ARGX) with an Outperform rating and a $404 price target. Argenx's Vyvgart (efgartigimod) is a neonatal Fc-Receptor (FcRn) antagonist that selectively reduces IgG levels and has the potential to address numerous IgG-mediated autoimmune diseases. According to the analyst, Argenx has demonstrated strong early launch execution for Vyvgart…

Benzinga

Raymond James Says PTC Therapeutics' CHMP Backing Is 'Under Exceptional Circumstances' What's Next

Last week, PTC Therapeutics Inc's (NASDAQ:PTCT) Upstaza (PTC-AADC; AAV2-based DDC gene therapy) received a CHMP opinion for approval under exceptional circumstances, says Raymond James. It maintains Outperform rating on the stock. The CHMP recommended Upstaza for AADC deficiency (AADCD) patients aged 18 months and older with a severe phenotype. According to the analysts, with the…

Benzinga

EXCLUSIVE: MSP Recovery CEO Explains How The Company's Revolutionary Tech Can Help Prevent Fraud

MSP Recovery Inc (NASDAQ: MSPR) shares are plunging Tuesday following the company's merger with special purpose acquisition company Lionheart Acquisition Corp II (NASDAQ: LCAP).

Benzinga

This Famed Company Is Working On A Potential Monkeypox Vaccine

As cases of monkeypox continue to rise, Moderna Inc (NASDAQ: MRNA) is probably working on its platform towards finding a vaccine shot against the disease.

Benzinga

Why Amazon Shares Are Diving Today

Amazon.com, Inc. (NASDAQ: AMZN) shares are trading lower by 3.04% at $2,084.69. Shares of retail and e-commerce companies are trading lower In sympathy with Abercrombie, which fell following its first-quarter report amid increased freight costs.

Benzinga

Mid-Afternoon Market Update: Nasdaq Down 300 Points; America's Car-Mart Shares Spike Higher

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 300 points on Tuesday.

1 … 449 450 451 452

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Intellectual Property

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.